3 Reasons Medtronic Inc.'s Stock Could Fall

Let’s look at three reasons Medtronic Inc.’s stock could fall.

Sep 2, 2014 at 1:01PM

Medtronic (NYSE:MDT) posted solid first-quarter earnings last month -- revenue climbed 5% year over year to $4.27 billion, while non-generally accepted accounting principles diluted earnings per share rose 6% to $0.93.

The medical-device maker reported 4% sales growth at its cardiac and vascular group, which accounts for over half of its top line. The restorative therapies group, which accounts for another 37% of sales, only rose 3% as a decline in the spine business offset growth in the neuromodulation and surgical businesses. The diabetes group, Medtronic's smallest business segment, grew 13% thanks to brisk sales of the MiniMed 530G, its first-generation "artificial pancreas."

MDT Chart

Source: YCharts.

Medtronic stock has remained flat since the earnings report, although it has outperformed the overall market to date in 2014.

While Medtronic's stock performance looks solid, investors should also understand the contrarian view to see why the share price might fall. But before we do so, note that while these points highlight Medtronic's vulnerabilities, they do not guarantee the stock will lose value.

Sluggish international growth
Last quarter, Medtronic's international revenue, which accounts for 45% of the company's top line, rose 3% year over year as reported, but only 2% on a constant currency basis. Comparing those results to growth in previous quarters, we can see that international growth is slowing as currency headwinds hurt Medtronic's top line.


2Q 2014

3Q 2014

4Q 2014

1Q 2015

International rev. growth (reported)





International rev. growth (constant currency)





Source: Quarterly reports.

Medtronic notably struggled in China and India, which respectively posted 6% revenue growth and a 7% decline in the first quarter. During the post-earnings conference call, CEO Omar Ishrak attributed that weak growth to challenges in distribution channels and management changes in China, along with distributor terminations and inventory rebalancing in India.

Although Ishrak said he believes both regions will eventually return to double-digit growth, sluggish performance in India and China could throttle international growth for a few more quarters.

The Covidien acquisition could fail
There are two reasons Medtronic wants to acquire Dublin-based Covidien (NYSE:COV) for $42.9 billion -- to lower its corporate tax rate with an inversion and to horizontally expand its medical device business across emerging markets.

Merging with Covidien would create a business that generates $13 billion in foreign revenue annually, with $3.7 billion coming from emerging markets. The combined company would help Medtronic expand its footprint by reaching 150 countries worldwide.

Although that sounds great for Medtronic, the company still must clear several hurdles to complete the deal. In addition to opposition in Congress, the merger will likely undergo an antitrust review by the Federal Trade Commission. Moreover, a Covidien shareholder recently sued to block the planned sale, claiming the Irish company intentionally blocked competing bids that could have raised its value.

While it is expected to close by the end of the year, or in early 2015, investors should remember that the Covidien deal isn't guaranteed yet.

Looming competition in the diabetes business
Finally, Medtronic's strong growth in its diabetes group might not last much longer.

Last September, Medtronic made history with FDA approval of the MiniMed 530G, which connects an insulin pump to a continuous glucose meter, or CGM, to produce a wearable artificial pancreas. The pump halts insulin delivery when glucose levels drop below a preset threshold. Medtronic is following up the 530G with the 640G, a second-generation device that can predictively shut off insulin before low thresholds are met. Although Medtronic dominates the U.S. market for now, competitors are quickly closing in.

The Animas Vibe and Dexcom G4 Platinum System -- two devices that work together, one from Johnson & Johnson (NYSE:JNJ) and the other from DexCom -- are already approved in Europe, Australia, and Canada, and could be approved soon in the U.S. When that happens, Medtronic's double-digit growth in the diabetes business -- which has continued for three consecutive quarters -- could cool off.

The Foolish takeaway
Medtronic is a solid company with three core businesses that aren't likely to fade away anytime soon.

However, prospective investors should do their due diligence and carefully consider the company's strengths against key weaknesses like sluggish international growth, the fate of the Covidien deal, and looming competitors in the insulin pump and CGM markets, before they dive in.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their nondividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers